Xiang Yang Lu
Chief Executive Officer en LAEKNA, INC. .
Fortuna: 36 M $ al 31/03/2024
Perfil
Xiang Yang Lu is the founder of Laekna Therapeutics (Shanghai) Co., Ltd.
and Laekna, Inc. both founded in 2016.
He is currently a Director at Laekna Ltd.
Dr. Lu's former positions include Executive Director at Novartis Institutes for Biomedical Research, Inc. and China Novartis Institutes for BioMedical Research Co., Ltd.
He was also a Venture Partner at Frontline Bioventures.
Dr. Lu received his doctorate from The University of North Carolina at Chapel Hill in 1995, his graduate degree from Nankai University in 1988, and his undergraduate degree from Nankai University in 1985.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LAEKNA, INC.
12.72% | 30/06/2023 | 49 603 870 ( 12.72% ) | 36 M $ | 31/03/2024 |
Cargos activos de Xiang Yang Lu
| Empresas | Cargo | Inicio |
|---|---|---|
| LAEKNA, INC. | Chief Executive Officer | 29/07/2016 |
Laekna Therapeutics (Shanghai) Co., Ltd.
 Laekna Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Laekna Therapeutics (Shanghai) Co. Ltd. focuses on drug discovery and development. The company was founded by Chris Xiangyang Lu in December 2016 and is headquartered in Shanghai, China. | Founder | 01/12/2016 |
| Laekna Ltd. | Director/Board Member | - |
Antiguos cargos conocidos de Xiang Yang Lu.
| Empresas | Cargo | Fin |
|---|---|---|
| China Novartis Institutes for BioMedical Research Co., Ltd. | Director/Board Member | 01/03/2016 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Director/Board Member | 01/03/2016 |
| Frontline Bioventures | Corporate Officer/Principal | - |
Formación de Xiang Yang Lu.
| The University of North Carolina at Chapel Hill | Doctorate Degree |
| Nankai University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| LAEKNA, INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
| Frontline Bioventures | Finance |
Laekna Therapeutics (Shanghai) Co., Ltd.
Laekna Therapeutics (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Laekna Therapeutics (Shanghai) Co. Ltd. focuses on drug discovery and development. The company was founded by Chris Xiangyang Lu in December 2016 and is headquartered in Shanghai, China. | Health Technology |
| China Novartis Institutes for BioMedical Research Co., Ltd. | |
| Laekna Ltd. |
- Bolsa de valores
- Insiders
- Xiang Yang Lu
